8 research outputs found

    Unthinkable Rebellion and the Praxis of the Possible: Ch'orti' Campesina/o Struggles in Guatemala's Eastern Highlands

    No full text
    This dissertation examines the production of rural struggle in Guatemala' indigenous eastern highlands, a place where after decades of silence, 36 years of civil war and two centuries of marginalization, the seemingly unthinkable—organized resistance and alternative proposals—became palpable. In the face of crisis, attempts to turn rural producers, into neoliberal subjects of credit resurrected the historical specter of dispossession and catalyzed an unlikely alliance to oppose unjust agrarian debt that transformed into a vibrant movement for defense of Maya-Ch'orti' territory. Yet, the contours of that alliance, its limits, and possibilities, its concrete splits and expansion are deeply linked to both place-based histories and memories of racialized dispossession, specific reworkings of 1990s discourses and practices of development and "peace"-making, and the concrete practice of starting from "common sense". I sieve a total of 26 months of participant-action research that spanned over four years with this nascent organization through a Lefebvrian method of rereading the past through the light of the present. Through this spatially and historically relational analysis based on critical ethnographic practice, I present an analysis where the present speaks powerfully to the past making three fundamental contributions. First, I produce an analytic that challenges narratives of spontaneous rebellion and/or seamless neoliberal development, demonstrating concretely how neither adequately address the relationship between racialized dispossession and ongoing rural efforts of repossession and or maintaining possession. Instead I draw attention to how the limits of neoliberal projects shape the contours of rebellion and spontaneous rebellions limit the aims of neoliberal projects: yet how these processes of entailment unfold hinges on particular articulations of past processes of dis/possession, development and difference. Second, I offer a rereading of the Guatemalan Civil War that hinges on rethinking the connections between the so-called ladino military East and indigenous militant West. In so doing I make break down divisive binaries that pervade Guatemalan common sense and offer a new understanding of Guatemala's 1980-83 racial genocide and creating openings for future alliances based not necessarily on an abstract sense of defense of territory or pan-Mayan identity, but in recognition of shared experiences and analyses of indigenous repression and resistance. Third, I show how particular articulations of race, class, gender and space are worked and reworked in and through the concrete practices of struggle and acquiescence, reaccommodation and flight that are shaped by the historical production of place. Rebellion past or present is neither unthinkable nor inevitable. And its potential for social change is bound to ongoing praxis

    Resilience and conflict : rethinking climate resilience through Indigenous territorial struggles

    Get PDF
    Resilience to climate change demands a transformation in social and political relations, but the literature has largely neglected how these are embedded within legacies of conflict. We explore the roles socioenvironmental conflicts play in the scaling up of transformation amidst ongoing settler colonial projects in Indigenous territories in Nicaragua. Drawing on insights from resilience, climate change, and critical agrarian studies, this article reframes resilience as a process produced within socioenvironmental conflicts, placing contestation and negotiation in the centre frame. By re-signifying the meanings and practices of resilience, Indigenous agrarian struggles contribute to 'eroding capitalism' and its entwinement with climate change

    Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial

    No full text
    Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA. Methods: Between Dec 19, 2006, and April 2, 2010, patients were enrolled in the ARISTOTLE trial at 1034 clinical sites in 39 countries. 18 201 patients with AF or atrial flutter were randomly assigned to receive apixaban 5 mg twice daily or warfarin (target international normalised ratio 2·0-3·0). The median duration of follow-up was 1·8 years (IQR 1·4-2·3). The primary efficacy outcome was stroke or systemic embolism, analysed by intention to treat. The primary safety outcome was major bleeding in the on-treatment population. All participants, investigators, and sponsors were masked to treatment assignments. In this subgroup analysis, we estimated event rates and used Cox models to compare outcomes in patients with and without previous stroke or TIA. The ARISTOTLE trial is registered with ClinicalTrials.gov, number NTC00412984. Findings: Of the trial population, 3436 (19%) had a previous stroke or TIA. In the subgroup of patients with previous stroke or TIA, the rate of stroke or systemic embolism was 2·46 per 100 patient-years of follow-up in the apixaban group and 3·24 in the warfarin group (hazard ratio [HR] 0·76, 95% CI 0·56 to 1·03); in the subgroup of patients without previous stroke or TIA, the rate of stroke or systemic embolism was 1·01 per 100 patient-years of follow-up with apixaban and 1·23 with warfarin (HR 0·82, 95% CI 0·65 to 1·03; p for interaction=0·71). The absolute reduction in the rate of stroke and systemic embolism with apixaban versus warfarin was 0·77 per 100 patient-years of follow-up (95% CI -0·08 to 1·63) in patients with and 0·22 (-0·03 to 0·47) in those without previous stroke or TIA. The difference in major bleeding with apixaban compared with warfarin was 1·07 per 100 patient-years (95% CI 0·09-2·04) in patients with and 0·93 (0·54-1·32) in those without previous stroke or TIA. Interpretation: The effects of apixaban versus warfarin were consistent in patients with AF with and without previous stroke or TIA. Owing to the higher risk of these outcomes in patients with previous stroke or TIA, the absolute benefits of apixaban might be greater in this population. Funding: Bristol-Myers Squibb and Pfizer. © 2012 Elsevier Ltd

    Apixaban versus warfarin in patients with atrial fibrillation

    No full text
    BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. RESULTS: The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P = 0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P = 0.42). CONCLUSIONS: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. Copyright © 2011 Massachusetts Medical Society. All rights reserved
    corecore